title: Studies on the protective efficacy and immunogenicity of Hsp70 and Hsp83 based vaccine formulations in Leishmania donovani infected BALB/c mice.
abstract: Visceral leishmaniasis, a chronic systemic infection, is the major cause of morbidity and mortality in many parts of world. The current drugs for the treatment of leishmaniasis are toxic, expensive, difficult to administer and becoming ineffective due to the emergence of drug resistance. In the absence of effective treatment, vaccination remains the only hope for control of the disease. We have evaluated the protective efficacy of two heat shock proteins (Hsp70 and Hsp83) in combination with two different adjuvants (MPLA and ALD) in Leishmania donovani infected inbred BALB/c mice. The proteins were isolated by SDS-PAGE and the mice were immunized subcutaneously with Hsp70+Hsp83, Hsp70+Hsp83+ALD and Hsp70+Hsp83+MPLA. These were challenged with 10(7) promastigotes of L. donovani. The animals were sacrificed on 30, 60 and 90 days post challenge for the assessment of parasite load and generation of cellular and humoral immune responses. The vaccines induced a strong protective response against experimental visceral leishmaniasis as shown by reduced parasite load in liver of all immunized groups as compared to the infected controls. The vaccines also led to the augmentation of DTH responses, increased levels of IgG2a, IFN-γ and IL-2. Both the adjuvants raised significantly the level of protection imparted by the proteins but MPLA was more effective in comparison to ALD.
authors.affiliation: Department of Zoology, Panjab University, Chandigarh 160014, India. kaurjaspreet37@gmail.com
authors.forename: Jaspreet
authors.initials: J
authors.lastname: Kaur
authors.forename: Tejinder
authors.initials: T
authors.lastname: Kaur
authors.forename: Sukhbir
authors.initials: S
authors.lastname: Kaur
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D000953:Antigens, Protozoan / Q000276:immunology; D016207:Cytokines / Q000097:blood; D004195:Disease Models, Animal; D018840:HSP70 Heat-Shock Proteins / Q000276:immunology / Q000627:therapeutic use*; D006968:Hypersensitivity, Delayed / Q000139:chemically induced / Q000276:immunology; D056724:Immunity, Humoral; D007893:Leishmania donovani / Q000276:immunology; D054332:Leishmaniasis Vaccines / Q000008:administration & dosage* / Q000276:immunology; D007898:Leishmaniasis, Visceral / Q000276:immunology / Q000517:prevention & control*; D008050:Lipid A / Q000031:analogs & derivatives / Q000494:pharmacology; D008099:Liver / Q000469:parasitology*; D051379:Mice; D008807:Mice, Inbred BALB C
chemical_list: D000276:Adjuvants, Immunologic; D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D016207:Cytokines; D018840:HSP70 Heat-Shock Proteins; D054332:Leishmaniasis Vaccines; D008050:Lipid A; C048436:monophosphoryl lipid A